Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Assets Average (2016 - 2025)

Zevra Therapeutics' Assets Average history spans 10 years, with the latest figure at $277.4 million for Q4 2025.

  • For Q4 2025, Assets Average rose 50.09% year-over-year to $277.4 million; the TTM value through Dec 2025 reached $277.4 million, up 50.09%, while the annual FY2025 figure was $231.4 million, 32.07% up from the prior year.
  • Assets Average reached $277.4 million in Q4 2025 per ZVRA's latest filing, up from $263.2 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $277.4 million in Q4 2025 to a low of -$426000.0 in Q3 2022.
  • Average Assets Average over 5 years is $138.8 million, with a median of $136.5 million recorded in 2021.
  • Peak YoY movement for Assets Average: skyrocketed 1105.22% in 2021, then plummeted 100.31% in 2022.
  • A 5-year view of Assets Average shows it stood at $135.1 million in 2021, then tumbled by 57.46% to $57.5 million in 2022, then soared by 84.58% to $106.1 million in 2023, then surged by 74.28% to $184.8 million in 2024, then surged by 50.09% to $277.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Assets Average are $277.4 million (Q4 2025), $263.2 million (Q3 2025), and $214.5 million (Q2 2025).